自我国的《药品生产质量管理规范》(GMP)颁布以来,贯彻实施这项工作已全面展开,并且取得了很大成绩,从而大大提高了我国制药工业的总体水平。但是,应该看到。在实施GMP过程中,由于我国的制药工业起点较低,国家财力有限,几年来尽管许多药厂投入大量资金进行企业改造。也只是对生产环境、条件,检测能力等方面进行了改善,而生产技术设备大多维持原状。致使技改后的制药企业生产能 Since the promulgation of GMP in our country, the implementation of this work has been carried out in full swing and great progress has been made, which has greatly raised the overall level of China’s pharmaceutical industry. However, it should be seen. In the implementation of GMP process, due to the low starting point of China’s pharmaceutical industry, the state financial resources are limited, although in recent years many pharmaceutical companies invested a lot of money for business transformation. Only on the production environment, conditions, testing capabilities and other aspects of the improvement, and most of the production technology and equipment to maintain the status quo. Resulting in technological transformation of the pharmaceutical production capacity